Patient blood management implementation in light of new Italian laws on patient's safety.
Clinical risk management
Medical liability
Patient blood management
Patient safety
Journal
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
ISSN: 1473-0502
Titre abrégé: Transfus Apher Sci
Pays: England
ID NLM: 101095653
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
15
03
2020
revised:
13
04
2020
accepted:
19
04
2020
pubmed:
24
5
2020
medline:
9
6
2021
entrez:
24
5
2020
Statut:
ppublish
Résumé
The present work aims to analyze the impact - from legal and medical perspective - of the recent Italian legislative provisions on the subject of healthcare safety, and how these affect current transfusion practices, also in light of the accumulation of evidence deriving from the implementation of the Patient Blood Management (PBM) program. The scientific evidence shows that PBM is a bundle of care that improves patient outcomes including mortality and morbidity, improves the quality of life of patients and the population, reduces healthcare costs and decreases consumption of blood components. These aspects should be largely sufficient to carry out an urgent implementation of PBM in Italian hospitals. However, it is now also possible to indicate a further incentive for implementation which is made up of medico-legal aspects and is characterized by the need to decrease the intrinsic risks of the use of blood products so as to protect doctors and hospitals from possible future medico-legal disputes regarding adverse transfusion events that could be effectively avoided.
Identifiants
pubmed: 32444279
pii: S1473-0502(20)30106-3
doi: 10.1016/j.transci.2020.102811
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
102811Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare no competing financial interests.